During the last session, Achilles Therapeutics Plc ADR (NASDAQ:ACHL)’s traded shares were 2.28 million, with the beta value of the company hitting 1.08. At the end of the trading day, the stock’s price was $0.90, reflecting an intraday loss of -24.76% or -$0.3. The 52-week high for the ACHL share is $1.76, that puts it down -95.56 from that peak though still a striking 17.78% gain since the share price plummeted to a 52-week low of $0.74. The company’s market capitalization is $36.82M, and the average intraday trading volume over the past 10 days was 0.23 million shares, and the average trade volume was 751.67K shares over the past three months.
Achilles Therapeutics Plc ADR (NASDAQ:ACHL) trade information
Achilles Therapeutics Plc ADR (ACHL) registered a -24.76% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -24.76% in intraday trading to $0.90, hitting a weekly high. The stock’s 5-day price performance is -24.13%, and it has moved by -30.55% in 30 days. Based on these gigs, the overall price performance for the year is -5.36%. The short interest in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) is 68900.0 shares and it means that shorts have 0.05 day(s) to cover.
Achilles Therapeutics Plc ADR (ACHL) estimates and forecasts
Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 77.00% this quarter and then drop -27.30% in the quarter after that.
While earnings are projected to return 16.09% in 2024, the next five years will return 5.20% per annum.
ACHL Dividends
Achilles Therapeutics Plc ADR is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Achilles Therapeutics Plc ADR (NASDAQ:ACHL)’s Major holders
Achilles Therapeutics Plc ADR insiders own 5.75% of total outstanding shares while institutional holders control 53.42%, with the float percentage being 56.67%. Syncona Portfolio Ltd is the largest shareholder of the company, while 21 institutions own stock in it. As of Jun 29, 2023, the company held over 11.09 million shares (or 27.08% of all shares), a total value of $10.48 million in shares.
The next largest institutional holding, with 2.56 million shares, is of Baker Brothers Advisors, LLC’s that is approximately 6.25% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $2.42 million.
Data provided on May 30, 2023 indicates that Fidelity NASDAQ Composite Index Fund owns about 21590.0 shares. This amounts to just over 0.05 percent of the company’s overall shares, with a $21590.0 market value.
